The Q/E27 polymorphism in the β2-adrenoceptor gene is associated with increased body weight and dyslipoproteinaemia involving triglyceride-rich lipoproteins

Journal of Internal Medicine

Volumn 247, Issue 6, 2000, Pages 651-656

  Ehrenborg, E ^a   Skogsberg, J ^a   Ruotolo, G ^a,b   Large, V ^a   Eriksson, P ^a   Arner, P ^a   Hamsten, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Body mass index; Genotyping; Mutation; Obesity; Very low density lipoprotein

Indexed keywords

BETA ADRENERGIC RECEPTOR; CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BODY MASS; DNA POLYMORPHISM; DYSLIPOPROTEINEMIA; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; SWEDEN;

EID: 0033923680     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2000.00669.x     Document Type: Article

References (22)

1. 1 Havel RJ. Conversion of plasma free fatty acids into triglycerides of plasma lipoprotein fractions in man. Metabolism 1961; 10: 1031-34.
2. 2 Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states: relationship to atherogenesis. Diabetes Care 1983; 14: 839-55.
3. 3 Lafontan M, Berlan M. Fat cell adrenergic receptors and the control of white and brown fat cell function. J Lipid Res 1993; 34: 1057-91.
4. 4 Reynisdottir S, Langin D, Carlström K, Holm C, Rössner S, Arner P. Effects of weight reduction on the regulation of lipolysis in adipocytes of women with upper-body obesity. Clin Sci 1995; 89: 421-29.
5. 5 Reynisdottir S, Wahrenberg H, Carlström K, Rössner S, Arner P. Catecholamine resistance in fat cells of women with upper-body obesity due to decreased expression of beta2-adrenoceptors. Diabetologia 1994; 37: 428-35.
6. 2-adrenoceptor polymorphisms: are they clinically important. Thorax 1996; 51: 351-53.
7. 2-adrenergic receptor: a protein with multiple membrane-spanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci USA 1987; 84: 46-50.
8. 8 Kobilka BK, Frielle T, Dohlman HG et al. Delineation of the intronless nature of the genes for the human and hamster beta 2-adrenergic receptor and their putative promoter regions. J Biol Chem 1997; 262: 7321-27.
9. 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33: 9414-19.
10. 10 Large V, Hellström L, Reynisdottir S et al. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associated with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 1997; 100: 3005-13.
11. 2-adrenergic receptor structure. Pulm Pharmacol 1995; 8: 1-10.
12. 2-adrenoceptor gene polymorphism on obesity in males and females. J Intern Med 1999; 245: 253-59.
13. 13 Ishiyama-Shigemoto S, Yamada K, Yuan X, Ichikawa F, Nonaka K. Association of polymorphisms in the β2-adrenergic receptor gene with obesity, hypertriglyceridaemia, and diabetes mellitus. Diabetologia 1999; 42: 98-101.
14. 14 Meirhaeghe A, Helbecque N, Cottel D, Amouyel P. β2-adrenoceptor gene polymorphism, body weight, and physical activity. Lancet 1999; 353: 896.
15. 15 Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. Plainview, NY: Cold Spring Harbor Lab Press, 1989.
16. 16 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acid Res 1988; 16: 1215.
17. 17 Carlson K. Lipoprotein fractionation. J Clin Pathol (Assoc Clin Pathol) 1973; 5(Suppl.): 32-37.
18. 18 Ott J. Associations between phenotypes and alleles. In: Analysis of Human Genetic Linkage. Baltimore: The Johns Hopkins University Press, 1991; 240-41.
19. 19 Barbe P, Millet L, Galitzki J, Lafontan M, Berlan M. In situ assessment of the role of beta1-, beta2-, and beta3-adrenoceptors in the control of lipolysis and nutritive blood flow in human subcutaneous adipose tissue. Br J Pharmacol 1996; 117: 907-13.
20. 20 Petraglia A, Scarpitta M, Ansalone D et al. Negligible metabolic effects of long-term oral treatment with a new beta 2-agonist: broxaterol. Int J Clin Pharmacol Res 1990; 10: 299-304.
21. 21 Arner P, Wahrenberg H, Lönnqvist F, Angelin B. Adipocyte beta-adrenoceptor sensitivity influences plasma lipid levels. Arterioscler Thromb 1993; 13: 967-72.
22. 22 Durrington PN, Brownlee WC, Large DM. Short-term effects of beta-adrenoceptor blocking drugs with and without cardioselectivity and intrinsic sympathomimetic activity on lipoprotein metabolism in hyperglyceridemic patient and in normal men. Clin Sci 1985; 69: 713-19